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http://dx.doi.org/10.1016/j.jfma.201
0929-6646/Copyright ª 2014, ElsevierAdvances in understanding the hepatitis C virus (HCV) life cycle and the urgent need to find
complementary direct-acting antiviral (DAA) therapies has led to substantial advancements
in treating chronic hepatitis C. The introduction of telaprevir and boceprevir in 2011 increased
the sustained virological response (SVR) rate from approximately 50% to > 70%, but this ther-
apy further restricted patient eligibility and is only approved for treating HCV genotype 1
infection. Interferon has long remained the backbone of HCV therapy and helps prevent viral
breakthrough. However, interferon has limited effectiveness and is associated with severe
adverse effects and toxicity, especially among cirrhotic patients. Moving to interferon-free
therapies should greatly improve SVR rates and offer new treatments for other HCV genotypes
and for ineligible patients or patients failing to respond to prior therapies. However, without
the relative safety of interferon to suppress viral escape, vigilance will be required to select
appropriate therapies and monitor resistance. Several DAAs are currently undergoing clinical
trials and will soon undergo the approval process. Goals of future HCV clinical research will
be to identify combinations of DAAs with high genetic barriers, investigate optimal treatment
doses and durations, and determine the role of ribavirin in DAA therapies.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
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Emerging treatments for chronic HCV 205therapydwas < 50% in patients with genotype 1 infection,
despite a daunting 48 week treatment regimen requiring
weekly interferon injections.3e5
Unsuccessful treatment can be classified as a “null
response” when the virus remains detectable throughout
treatment. “Viral breakthrough” is when the virus becomes
transiently undetectable but rebounds before the end of
treatment. “Relapse” is when the virus becomes transiently
undetectable but then reappears after the end of therapy. In
2011, the approval of the direct-acting antiviral (DAA) drugs
telaprevir (VX-950/MP-424) and boceprevir increased the
sustained virological rate to 70e80%, depending on genetic
factors and previous treatment history.6,7 Despite these
gains, these first-generation protease inhibitors will soon face
obsolescence as new DAAs progress through clinical trials.
Molecular insight into the HCV life cycle gained through
advances in cell culture and small animal models has
facilitated the development of DAAs, which are small
molecule therapies designed to directly target viral prod-
ucts at various steps in the viral life cycle. All HCV products
appear to be required for replication and drugs that target
each viral product are under investigation (Fig. 1). This DAA
approach promises high specificity and fewer adverse ef-
fects, although these benefits are offset by high costs and a
higher risk of resistance. The problem of resistance can be
partly addressed by the coadministration of several DAAs
that target different viral products to create a higher bar-
rier to resistance. The problem of cost may be managed
partly by careful patient selection. To overcome the limi-
tations of telaprevir and boceprevir, priorities for future
DAA development include improved potency; improved
genotypic coverage, especially against genotype 4; a higher
barrier to resistance; and better safety profiles.8 Secondary
priorities include shorter treatment duration, better pa-
tient compliance through reduced pill burden, minimized
drugedrug interactions, and lower cost.
A major goal of HCV research is the development of safe
and effective short duration all-oral, interferon-free thera-
pies. Interferon is poorly tolerated, especially among elderly
and cirrhotic patients, and is associated with fever, tachy-
cardia, headache, joint or muscle pain, fatigue, skin lesions,
depression, and neuropsychiatric effects.9,10 Compared to
other chronic diseases such as human immunodeficiencyFigure 1 The hepatitis C virus (HCV) genome architecture. The
proteases cleave the structural core and envelope proteins, where
other nonstructural proteins. Clinically relevant resistance mutatiovirus (HIV), the drug development time for HCV is fortu-
nately benefitted by a short treatment duration and by the
use of open-label studies and alternative end points such as
SVR12 (i.e., the SVR at 12weeks is the end point instead of 24
weeks). By contrast, HCV clinical trials are complicated by
inter- and intragenotype variability; prior patient treatment
history; patients with cirrhosis or liver transplantation; HIV
or hepatitis B virus (HBV) coinfection; and a high risk of
resistance, unless accompanied by peginterferon and riba-
virin or in combination with other DAAs. Clinical trials often
initially exclude such patients; however, these patients are
often the ones who will benefit the most from interferon-
free therapies. Recent studies have increasingly begun to
focus on some of these heterogeneous and difficult-to-treat
patient subgroups.
NS3/4A protease inhibitors
Direct-acting antivirals act by specifically targeting viral
components. Telaprevir, one of the first United States Food
and Drug Administration (US FDA)-approved protease in-
hibitors (PIs), mimics the carboxy-terminal region of the HCV
NS3/4 serine protease.11 The 9.6 kb HCV RNA genome con-
tains a single open reading frame and encodes a single
approximately 3000 amino acid polyprotein that must be
cleaved into three structural proteins, which includes the
core protein, two envelope proteins, and six nonstructural
proteins. Cellular proteases cleave the structural proteins,
whereas virally encoded proteases NS2 and NS3, and the NS3
cofactor NS4A, cleave the remaining polyprotein at four
specific sites to produce the nonstructural proteins. Because
NS3/4A also interferes with innate immune activity by
degrading key immune signalingmolecules, targetingNS3/4A
prevents cleavage of the nonstructural proteins and inhibits
the ability of the virus to evade the immune response.12e14
Boceprevir triple therapy
Several studies have demonstrated the increased effec-
tiveness of boceprevir or telaprevir triple therapy,
compared to the standard of care with peginterferon and
ribavirin combination therapy.15 Boceprevir requires aHCV RNA genome is initially translated as a polyprotein. Host
as the viral encoded NS3/NS4A protease cleaves itself and the
ns have been detected for each class of direct-acting antiviral.
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weeks, which is intended to lower HCV RNA levels and
reduce the risk of viral breakthrough resulting from the
selection for boceprevir-resistant strains.16 The Serine
Protease Inhibitor Therapy 2 (SPRINT-2) trial and the
Retreatment with HCV Serine Protease Inhibitor Boceprevir
and PegIntron/Rebetol 2 (RESPOND-2) trial assessed the
effect of triple therapy with boceprevir plus peginterferon
and ribavirin in 1097 treatment-naı¨ve patients and 403
previously treated patients, respectively. In both studies,
patients received peginterferon plus ribavirin for 4 weeks
(i.e., the lead-in period), after which they were assigned to
one of three groups: (Group 1, the control group) pegin-
terferon, ribavirin, and placebo for 44 weeks; (Group 2)
peginterferon, ribavirin, and boceprevir for 24 weeks
(SPRINT-2) or 32 weeks (RESPOND-2), and an additional 20
weeks (SPRINT-2) or 12 weeks (RESPOND-2) if HCV RNA
remained detectable; or (Group 3) peginterferon, ribavirin,
and boceprevir for 44 weeks. In the SPRINT-2 study, 40% of
patients in Group 1, 67% of patients in Group 2, and 68% of
patients in Group 3 achieved SVR; 21% of boceprevir-
treated patients underwent anemia-related dose re-
ductions.17 In the RESPOND-2 study, only 21% of patients in
the control group achieved SVR, compared to 59% of pa-
tients in Group 2 and 66% of patients in Group 3, although
anemia occurred frequently in the boceprevir-treated pa-
tients and was treated with erythropoietin.18
Telaprevir triple therapy
A major difference between telaprevir and boceprevir is
that a lead-in phase is not required with telaprevir triple
therapy because of its stronger anti-HCV potency. The
Phase III (ADVANCE) study reported SVR rates of 75% after
12 weeks of telaprevir, peginterferon, and ribavirin triple
therapy and 69% after 8 weeks, compared to 44% for
peginterferon and ribavirin alone in treatment-naı¨ve pa-
tients6; however, adverse events such as pruritis, rash, and
nausea were higher in the telaprevir treatment arms. In the
ILLUMINATE noninferiority study examining treatment
duration, 540 treatment-naı¨ve patients were treated with
telaprevir triple therapy for 12 weeks, which was followed
by peginterferon and ribavirin alone for an additional 4
weeks (T12PR24) or 28 weeks (T12PR48), depending on
whether the patient had an extended rapid virological
response (i.e., undetectable HCV RNA at Week 4 and Week
12).19 Ninety-two percent of patients in the T12PR24 group
and 88% of patients in the T12PR48 group achieved SVR,
although rash and anemia were common and sometimes
severe, which led to discontinuation in 18% of patients. The
REALIZE study demonstrated substantial improvements in
SVR rates among previously treated patients: 64% SVR rate
after 12 weeks of telaprevir triple therapy, 66% SVR rate
when preceded by a 4-week lead-inphase, and 17% SVR rate
after peginterferon and ribavirin alone.7 Based on the
strong improvement among prior relapsers, the FDA
approved response-guided therapy with early termination
after 24 weeks for prior relapsers who maintained unde-
tectable HCV RNA at Week 4 and Week 12 (i.e., extended
rapid virological response).20 A Phase III study in Japan re-
ported an SVR rate of 73% after 12 weeks of triple therapy
that was followed by 12 weeks of combination therapy,compared to an SVR rate of 49% among patients assigned to
48 weeks of combination therapy.21 However, adverse ef-
fects such as anemia and skin disorders were approximately
twice as common among patients treated with triple ther-
apy (38% and 47%, respectively) than among patients
treated with combination therapy (18% and 24%, respec-
tively). Another Japanese Phase III study reported SVR rates
of 88% among prior relapsers and 34% among prior non-
responders, but most patients experienced skin disorders
(82%) and nearly all patients required ribavirin dose
reduction (99%).22 Twenty-one percent of patients dis-
continued telaprevir only, and 16% of patients discontinued
all drugs. Because the dosage of telaprevir is not adjusted
by body weight, anemia is of particular concern in Japan
because of the larger proportion of older female patients
and the typically lower body weight of Japanese patients,
compared to patients in many Western countries.23
Adverse events associated with telaprevir and
boceprevir triple therapy
The addition of boceprevir or telaprevir to a treatment
regimen containing peginterferon and ribavirin leads to a
higher frequency of adverse events, although many adverse
events reported in clinical trials are also those associated
with peginterferon and ribavirin treatment. Boceprevir
triple therapy is associated with increased risk of neu-
tropenia, dysgeusia, anemia, and thrombocytopenia,
compared to peginterferon plus ribavirin dual therapy.15,24
In clinical trials, approximately 33% of patients experienced
neutropenia and 25% of patients experienced anemia,
although the frequency of discontinuation was not greater.
Telaprevir triple therapy is associated with increased fre-
quency of anemia, pruritis, and rash in up to 50% of pa-
tients, and associated with severe events in up to 5e10% of
patients.15,24 Anorectal adverse events and rates of
discontinuation are higher among patients treated with
telaprevir triple therapy than among patients treated with
peginterferon and ribavirin alone.
Telaprevir and boceprevir in cirrhotic patients
The risk of adverse events is particularly important in the
treatment of cirrhotic patients. In the Compassionate Use
of Protease Inhibitors in Viral C Cirrhosis (CUPIC) study,
previously treated patients with compensated cirrhosis
were treated for 48 weeks with peginterferon and ribavirin
and either boceprevir or telaprevir.25 Depending on the
response to previous therapy, patients achieved a SVR rate
of 19e74% with telaprevir and a rate of 0e54% with boce-
previr, but severe adverse events occurred in 50% of
patients.
Telaprevir and antiviral resistance
Telaprevir triple therapy substantially improves the SVR rate
over peginterferon plus ribavirin, especially among
treatment-experienced patients; however, if administered
alone, telaprevir induces rapid selection for resistance var-
iants.26,27 Therefore, telaprevir must be administered as
part of triple therapy with peginterferon and ribavirin to
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only increases the risk of adverse effects and imposes
further restrictions on an already restrictive therapy.
Because of substantial intergenotypic variation in the NS3
domain, the high specificity of first-generation PIs limits
their application to genotype 1 infections and results in a low
barrier to resistance.28 Even within genotype 1, resistance
occurs more frequently in genotype 1a than in genotype 1b
because of a synonymous codon at R155 that reduces the
number of nucleotide changes required to cause an amino
acid substitution.29 Resistance mutations tend to compro-
mise viral fitness, but compensatory mutations such as V36 M
that restore viral fitness often occur, which allows the virus
to compete more effectively with the wild type virus, even
in the absence of the drug.30 High cross-resistance unfortu-
nately also implies that resistance to one PI is likely to confer
resistance to other PIs in the same class. Discontinuing
telaprevir or boceprevir therapy is consequently recom-
mended in the event of viral breakthrough. Triple therapy
also involves a heavy pill burden with weekly injections of
peginterferon, twice-daily ribavirin intake, and twice (q12)
or three times (q8) daily telaprevir or boceprevir intake.
Telaprevir must also be taken after a high fat meal (20 g)
such as a bagel with cream cheese or cup of ice cream, which
imposes inconvenient lifestyle changes and risks poor pa-
tient compliance.
Second-wave protease inhibitors
Second-wave PIs (Table 1) attempt to address these limi-
tations through an incremental approach to increase theTable 1 NS3/4A protease inhibitors undergoing development.
NS3/4A protease inhibitors Manufacturer Status Struct
First-generation, first-wave
Telaprevir
(VX-950, Incivek)
Janssen Approved Linea
Boceprevir
(SCH503034, Victrelis)
Merck Approved Linea
First-generation, second-wave
Simeprevir
(TMC-435, Olysio)
Tibotec Approved Macro
Faldaprevir
(BI-201335)
Boehringer
Ingelheim
Phase III Linea
Asunaprevir
(BMS-650032)
BristoleMyers
Squibb
Pending
approval
Linea
ABT-450/r Abbvie Phase III Linea
Danoprevir
(ITMN-191, RG 7227)
Roche Phase II Macro
Sovaprevir (ACH-1625) Achillion Phase II Linea
Vedroprevir (GS-9451) Gilead Phase II Macro
IDX320 Idenix Phase II Macro
Vaniprevir (MK-7009) Merck Phase III Macro
Second-generation
MK-5172 Merck Phase III Macro
ACH-2684 Achillion Phase II Macro
ALTZ alanine aminotransferase; BarrierZ genetic barrier to resistan
peginterferon plus ribavirin combination therapy.barrier to resistance and to improve activity against other
genotypes, especially the common but difficult-to-treat
genotype 4 for which there are currently few treatment
options. Second-wave PIs also aim to improve patient
compliance and tolerability by reducing the dosing
schedule to one or two administrations per day and by
improving the safety profile.31 Second-generation PIs
attempt to go a step further and provide pangenotypic
activity against all HCV genotypes and resistance mutations
that affect the first-generation PIs.
Simeprevir triple therapy
Simeprevir (TMC-435) is a once-daily macrocyclic PI with a
long half-life that is active against genotypes 1, 2, 4, 5, and
6.32 Simeprevir has been approved in the United States of
America (150 mg dose) and in Japan (100 mg dose) for use in
triple therapy with peginterferon and ribavirin. In the Phase
III QUEST-1 clinical trial, 394 treatment-naı¨ve patients with
genotype one in 13 countries were randomized to treat-
ment with peginterferon-a2a plus ribavirin and either
simeprevir or a placebo for 12 weeks, followed by response-
guided therapy for 24 weeks or 48 weeks.33 Eighty percent
of patients in the simeprevir group achieved SVR12,
compared to 50% in the placebo group. Fatigue and head-
ache were the most common adverse events but these
events occurred at similar frequencies in the simeprevir
group and in the placebo group. The QUEST-2 study design
was similar, but it included treatment arms to compare
peginterferon-a2a versus peginterferon-a2b and two riba-
virin dosages.34 Eighty-one percent of patients in theure Barrier Adverse effects Gt
r (covalent) Low rash, anemia, pruritis 1
r (covalent) Low anemia, dysgeusia 1
cycLic Moderate anemia, bilirubin 1,2,5,6
r Moderate rash, jaundice,
nausea, diarrhea
1
r Moderate PR 1,4
r Moderate fatigue, headache,
nausea
1
cycLic High nausea, diarrhea,
neutropenia, ALT
1,2,4
r Moderate PR 1
cycLic Moderate PR 1
cycLic Moderate PR 1,2,3,4
cycLic Moderate nausea 1
cycLic Moderate PR 1,2,4,5,6
cycLic High PR 1,2,4,5,6
ce; GtZ genotype; PRZ adverse effects are similar to those of
208 C.N. Hayes, K. Chayamasimeprevir group achieved SVR12, compared to 50% in the
placebo group. The incidence of anemia was similar in both
groups, but rash and photosensitivity were more common in
the simeprevir group. The Phase III PROMISE study exam-
ined the effect of 12 weeks of peginterferon-a2a plus
ribavirin and either simeprevir or placebo, followed by
response-guided therapy in prior relapsers.35 The SVR12
rate was 79% in the simeprevir group and 36% in the placebo
group. Both groups had a similar incidence and severity of
adverse events.
In the CONCERTO-1 Phase III trial in Japan, 183 treat-
ment-naı¨ve patients were randomized to simeprevir,
peginterferon, and ribavirin for 12 weeks. This was followed
by response-guided therapy for 12 weeks or 36 weeks or by a
placebo for 12 weeks, followed by 36 weeks with peginter-
feron and ribavirin.36 Sustained virological response at 12
weeks was achieved in 89% of simeprevir-treated patients,
compared to 62% of placebo-treated patients. In the
CONCERTO-2 and CONCERTO-3 open-label Phase III trials,
155 prior nonresponders and relapsers were treated with
simeprevir, peginterferon, and ribavirin for 12 weeks or 24
weeks, followed by response-guided therapy. Fifty-three
percent of prior nonresponders and 96% of prior responders
achieved SVR12, but 13% of prior nonresponders experi-
enced viral breakthrough and 39% experienced viral
relapse.37 In a Phase IIb, randomized, double-blind, pla-
cebo-controlled trial (NCT00980330), 462 genotype 1 prior
relapsers and nonresponders were treated with peginter-
feron, ribavirin, and simeprevir or a placebo for 12 weeks, 24
weeks, or 48 weeks.38 The SVR rates were significantly
higher in the simeprevir treatment arms, regardless of prior
treatment response, and up to 89% among prior relapsers.Polymerase inhibitors
The PIs act during the early stage of the HCV life cycle by
interfering with polyprotein cleavage, whereas other DAAs
target different aspects of viral replication. PolymeraseTable 2 NS5B polymerase inhibitors undergoing development.
Type Polymerase inhibitors Manufacture
Nucleoside inhibitors
Sofosbuvir (GS-7977) Gilead Scien
Mericitabine (RG-7218) Roche
Non-nucleoside inhibitors
Thumb I inhibitors
Deleobuvir (BI 207127) Boehringer I
Thumb II inhibitors
GS-9669 Gilead Scien
Filibuvir (PF-868554) Pfizer
VX-222 Vertex
BMS-791325 Bristol-Myer
Palm I inhibitors
Dasabuvir (ABT-333) Abbott
ABT-072 Abott
Setrobuvir (ANA-598) Roche
Palm II inhibitors
Tegobuvir (GS-9190) Gilead Scieninhibitors target HCV NS5B RNA-dependent RNA polymerase
(RdRp/NS5B; Table 2). This low-fidelity polymerase syn-
thesizes a negative strand RNA, which is then used to pro-
duce multiple positive strand copies of the HCV genome for
replication and translation.39 Two different types of poly-
merase inhibitorsdnucleoside inhibitors (NIs) and non-
nucleoside inhibitors (NNIs)dare undergoing clinical trials.
Nucleoside inhibitors are similar to naturally occurring
nucleotides; however, when they are incorporated into the
elongating RNA sequence, they inhibit the RdRp active site
and cause chain termination.40 An NI is administered as a
prodrug and must be phosphorylated to become an active
nucleoside triphosphate. In principle, NIs have a low barrier
to resistance because of the potential for single amino
substitutions to confer resistance. In practical terms, an
effective barrier to resistance is relatively high, owing to
strong conservation of the active site among all HCV ge-
notypes and the poor fitness of resistant variants.40 In fact,
the NIs have the highest barrier to resistance among DAAs
examined to date.31
The NIs directly interfere with the RdRp active site,
whereas the NNIs suppress RdRp activity by binding to
allosteric sites away from the active site. The NNIs are only
active against genotype 1 and have lower antiviral potency
and a lower barrier to resistance. Resistance mutations also
do not necessarily compromise viral fitness. However,
several NNIs under investigation, such as the thumb I/II
inhibitors and palm I/II inhibitors, may provide comple-
mentary protection by targeting different regions of the
molecule.
Sofosbuvir, a nucleoside polymerase inhibitor, was
approved in the United States for use in combination with
ribavirin to treat genotypes 2 and 3 and for use in combi-
nation with peginterferon and ribavirin to treat genotypes 1
and 4. The safety and efficacy of sofosbuvir was evaluated
in a Phase II clinical trial in which 122 treatment-naı¨ve
genotype 1 patients were randomly assigned to 200 mg or
400 mg of sofosbuvir plus peginterferon and ribavirin for 12
weeks, followed by 12 weeks or 36 weeks ofr Status Genotype
ces Approved 1e6
Phase III 1,4
ngelheim Phase II 1
ces Phase I
Phase II 1
Phase II 1
s Squibb Phase III
Pending approval 1
Phase II 1
Phase II 1
ces Phase II 1
Table 3 NS5A inhibitors undergoing development.
NS5A inhibitors Manufacturer Status
First-generation
Daclatasvir
(BMS-790052)
BristoleMyers Squibb Phase III
Ledipasvir
(GS-5885)
Gilead Sciences Phase III
Ombitasvir
(ABT-267)
AbbVie Phase III
PPI-668 Presidio Pharmaceuticals Phase II
PPI-461 Presidio Pharmaceuticals Phase II
ACH-2928 Achillion Phase II
GSK-2336805 GlaxoSmithKline Phase II
BMS-824393 BristoleMyers Squibb Phase II
Samatasvir (IDX719) Idenix Pharmaceuticals Phase II
Second generation
MK-8742 Merck Phase II
ACH-3102 Achillion Phase II
GS-5816 Gilead Sciences Phase II
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SVR12 rates were 90% in the 200 mg group, 91% in the
400 mg group, and 58% in the placebo group. Adverse
events such as fatigue, headache, nausea, and chills were
consistent with those of peginterferon and ribavirin; in
addition, discontinuation because of adverse events was
similar among the groups.41
In the open-label Phase II Sofosbuvir with Pegylated
Interferon alfa-2a and Ribavirin for Treatment-naive Pa-
tients with Hepatitis C Genotype-1 Infection (ATOMIC)
study, 316 treatment-naı¨ve patients with genotype 1, 4, or
6 were randomized to 12 weeks or 24 weeks of sofosbuvir
plus peginterferon and ribavirin or to 12 weeks of triple
therapy that was followed by 12 weeks of sofosbuvir with or
without ribavirin.42 In all treatment arms, SVR12 rates of
87e89% were achieved among genotype 1 patients, and
there was no benefit in extending sofosbuvir treatment
beyond 12 weeks. In the single-arm, open-label Phase III
NEUTRINO study, 327 treatment-naı¨ve patients with geno-
type 1 or genotype 4 were treated with 12 weeks of
sofosbuvir plus peginterferon and ribavirin, which resulted
in a SVR12 rate of 90%.43 In a noninferiority trial, 499 pa-
tients with genotype 2 or genotype 3 were randomly
assigned to receive 12 weeks of either sofosbuvir and
ribavirin or peginterferon and ribavirin, which resulted in a
SVR12 rate of 67% in both groups.NS5A inhibitors
The HCV polyprotein is post-translationally processed into
10 viral proteins. The E1, E2, and core structural proteins
are incorporated into the virus particle, whereas the
nonstructural proteins NS3, NS4A, NS5A, and NS5B are
essential components of the replication complex,44 which is
an endoplasmic reticulum-associated membrane structure
essential for replication of the HCV genome. Each HCV
protein is required for replication, whereas most drug dis-
covery efforts have focused on the enzymes NS3 and NS5B;
however, NS5A has no known enzymatic activity.45 The
successful interferon-free combination therapies require
multiple complementary targets to raise the barrier to
resistance. The protein NS5A is a promising target because
of its pleiotropic roles in establishing the replication com-
plex, in viral assembly, and in inhibiting apoptosis; how-
ever, the lack of enzymatic activity has complicated drug
development efforts. The mechanism by which NS5A regu-
lates replication is unclear, but the protein binds to RNA
and interacts directly with NS5B RdRp, which catalyzes
negative strand synthesis.46 NS5A also interacts with the
host protein cyclophilin A, and recruits apolipoprotein E.
Cell-based replicon screening identified several anti-HCV
compounds that act through NS5A.45 These drugs have
demonstrated high specificity and potency at picomolar
concentrations, and have pangenomic activity and a high
barrier to resistance (Table 3). The mechanism of NS5A
inhibitors is unknown but may involve multiple effects such
as inhibiting hyperphosphorylation, which appears to be
required for viral replication.47 Several NS5A inhibitors bind
to NS5A domain 1 and prevent RNA binding without
affecting NS5A dimerization.48 Even though NS5A inhibitors
are among the most potent antiviral molecules known,resistance variants are likely to pre-exist at low frequencies
in patients prior to exposure because of the quasi-species
nature of the virus, and may be rapidly selected after the
administration of an NS5A inhibitor. In the event of viral
breakthrough, the viral titer rebounds to pretreatment
levels with few effects on fitness.47 Therefore, NS5A in-
hibitors should be used in combination with drugs with
nonoverlapping resistance profiles.
Interferon-free combination therapies
Interferon has long formed the backbone of HCV therapy,
but interferon therapy requires difficult long term treat-
ment and is associated with adverse effects that prevent
some patients from receiving treatment, particularly
among cirrhotic patients for whom interferon is toxic.
Several common human and viral genetic polymorphisms
also affect interferon sensitivity, and thereby reduce the
effectiveness of therapy in affected patients. However, the
inclusion of interferon with DAAs helps to prevent the
emergence of resistance variants under the strong selective
pressure of the drug. Because resistance is likely to arise in
monotherapy involving any DAA, interferon-free trials are
designed as combinations of two or more DAAs that
together confer a high overall barrier to resistance
(Table 4).50e59,61e70 This often requires joint examination
of two investigational drugs. Most current trials continue to
use ribavirin because of its oral delivery and effectiveness
in suppressing resistance, but avoiding ribavirin-induced
anemia is another goal of HCV therapy.
Asunaprevir and daclatasvir
One of the first reported interferon-free therapies was the
combination of the protease inhibitor asunaprevir with the
NS5A inhibitor daclatasvir.49,50 In an open-label Phase III
study (NCT01497834), 222 interferon-intolerant patients or
prior nonresponders with genotype 1 were treated with
Table 4 Interferon-free combination therapies.
Study Trial Patients Weeks Response
Asunaprevir and daclatasvir
Kumada et al, 201451 Phase III 222 gt1 IFN-intolerant
or prior nonresponders
24 SVR24: 87% IFN-intolerant 81%
prior nonresponders
Lok et al, 201450 Phase IIa 101 gt1b 24 SVR12: 78%
Manns et al, 201452 Phase III 745 diverse gt1b 24 SVR12: 85% (90% tx-naı¨ve patients)
Asunaprevir, daclatasvir, and BMS-791325
Everson et al, 201453 Phase IIa 66 noncirrhotic, tx-naı¨ve gt1 12 or 24 SVR12: 92%
Daclatasvir and sofosbuvir
Sulkowski et al, 201454 Open-label 211 patients gt1, gt2, or gt3 12 or 24 SVR12: gt1, 98%; gt2, 92%; gt3, 89%
Ledipasvir and sofosbuvir
Afdhal et al, 201455,56 Phase III 865 gt1 tx-naı¨ve; 440 gt1
prior nonresponders
12 SVR12: tx-naı¨ve, 96%; prior
nonresponders, 94%
Kowdley et al, 201457 Phase III 647 gt1, tx-naı¨ve, noncirrhotic 8 SVR12: 94%
Sofosbuvir and ribavirin
Jacobson et al, 201358 Phase III 278 gt2/3, IFN-ineligible;
201 previously treated
12 SVR12: IFN-ineligible, 78%;
previously treated, 50%
Zeuzem et al, 201459 Unblinded 21 gt2, 328 gt3 cirrhotic or
previously treated
12 SVR12: gt2, 93%; gt3, 85%
ABT-450/r, dasabuvir (ABT-333), and ribavirin
Poordad et al, 201361 Phase IIa 50 gt1, tx-naı¨ve or prior
nonresponder
12 SVR12: tx-naı¨ve, 95%;
prior nonresponders, 47%
ABT-450/r, ombitasvir, dasabuvir, and ribavirin
Feld et al, 201462 Phase III 631 gt1, tx-naı¨ve 12 SVR12: gt1a, 95%; gt1b, 98%
Ferenci et al, 201463 Phase III 419 gt1a, 305 gt1b 12 SVR12: gt1b, 99.5%; gt1a, 97%
Zeuzem et al, 201464 Phase III 394 gt1, prior nonresponders 12 SVR12: 96%
Poordad et al, 201465 Phase III 380 gt1 Child-Pugh A cirrhotics 12 or 24 SVR: 12 weeks, 91%; 24 weeks, 96%
Faldaprevir (BI 201335), deleobuvir (BI 207127), and ribavirin
Zeuzem et al, 201366 Phase IIb 362 gt1, tx-naı¨ve 16, 28, or 40 SVR12: 69%
ABT-450/r, ABT-072, and ribavirin
Lawitz et al, 201367 Phase IIa 11 gt1 tx-naı¨ve 12 SVR: 91%
Miracitabine (R7128), danoprevir (RG7227/ITMN-191), and ribavirin
Gane et al, 201468 Phase IIb 169 gt1, tx-naı¨ve 12 or 24 SVR24: gt1a, 25%; gt1b, 64%
MK-5172, MK-8742, and ribavirin
Hezode et al, 201469 Phase II 156 gt1, tx-naı¨ve 12 SVR12: 94e98%
Lawitz et al, 201470 Phase II 254 cirrhotic or prior
nonresponders
12 or 18 HCV RNA LLQ at week 4, 94e100%
gt1egt6 Z genotype 1egenotype 6; HCV Z hepatitis C virus; IFN Z interferon; LLQ Z lower limit of quantification; SVR12 or
SVR24 Z sustained virological response at 12 or 24 weeks; tx-naı¨ve Z treatment-naı¨ve.
210 C.N. Hayes, K. Chayamaonce-daily daclatasvir and twice-daily asunaprevir for 24
weeks.51 Eighty-seven percent of intolerant patients and
81% of prior nonresponders achieved SVR24. Ninety-one
percent of cirrhotic patients achieved SVR24, compared
to 84% of noncirrhotic patients. Thirteen percent of pa-
tients discontinued therapy because of nonresponse or
because of adverse effects that typically included naso-
pharyngitis, elevated alanine aminotransferase (ALT) level,
headache, diarrhea, or fever.
In a Phase IIa, open-label study, 101 patients with ge-
notype 1b were randomly assigned to once-daily daclatasvir
and once- or twice-daily asunaprevir with or without
peginterferon and ribavirin for 24 weeks.50 Seventy-eight
percent of daclatasvir plus twice-daily asunaprevir pa-
tients achieved SVR12 and 95% of patients achieved SVR12
in quadruple therapy with peginterferon plus ribavirin.
Common adverse events included headache, diarrhea, and
weakness. Virological breakthrough was higher in patientswith genotype 1a, which suggests that patients with geno-
type 1 should be treated according to subtype.
In the recent HALLMARK DUAL Phase III study, 305
treatment-naı¨ve patients with genotype 1b were randomly
assigned to treatment with 24 weeks of asunaprevir and
daclatasvir or to 12 weeks of placebo, which was followed
by entry into another study.52 Four hundred and forty
interferon-ineligible/intolerant patients or null/partial
response patients were treated with asunaprevir and
daclatasvir for 24 weeks. The SVR12 rates were similar in
cirrhotic (85%) patients and noncirrhotic (84%) patients.
The SVR12 rate was 90% in treatment-naı¨ve patients and
82% in null/partial patients and in ineligible patients.
Asunaprevir, daclatasvir, and BMS-791325
In a Phase IIa open-label study (NCT01455090), 66 non-
cirrhotic treatment-naı¨ve patients with genotype 1 were
Emerging treatments for chronic HCV 211treated for 12 weeks or 24 weeks with triple therapy that
included asunaprevir, daclatasvir, and the NNI polymerase
inhibitor BMS-791325.53 Ninety-two percent of patients
achieved SVR12, whereas one patient relapsed and two
patients experienced viral breakthrough. Adverse events
were mild and included headache, weakness, and gastro-
intestinal symptoms.
Daclatasvir and sofosbuvir
Daclatasvir was also paired with sofosbuvir with or without
ribavirin in a recent once-daily, all-oral open-label study in
211 patients with genotypes 1, 2, or 3.54 Ninety-eight
percent of the patients with genotype 1 achieved SVR12,
regardless of previous treatment failure with PIs. The SVR
was slightly lower at 92% for patients with genotype 2 and
89% for patients with genotype 3. Adverse events included
fatigue, headache, and nausea.
Ledipasvir and sofosbuvir
Several clinical trials have also paired sofosbuvir with the
NS5A inhibitor ledipasvir. In a Phase III open-label study
(NCT01701401), 865 treatment-naı¨ve patients with geno-
type 1 were randomly assigned to fixed-dose, once-daily
ledipasvir and sofosbuvir combination therapy with or
without ribavirin for 12 weeks or 24 weeks.55,56 The SVR12
rates ranged from 96% after 12 weeks of ledipasvir and
sofosbuvir therapy to 99% in patients with 24 weeks of
ledipasvir and sofosbuvir plus ribavirin triple therapy. In a
related Phase III open-label study (NCT01768286), 440 pa-
tients with genotype 1 who failed to achieve SVR during
previous peginterferon plus ribavirin therapy with or without
telaprevir/boceprevir were randomly assigned to 12 weeks
or 24 weeks of ledipasvir and sofosbuvir therapy with or
without ribavirin.55 Despite nonresponse to previous therapy
and inclusion of patients with cirrhosis, the SVR12 rates
ranged from 94% after 12 weeks of ledipasvir plus sofosbuvir
dual therapy to 99% after 24 weeks of ledipasvir plus sofos-
buvir with or without ribavirin. Common adverse events
included fatigue, headache, and nausea in both studies.
Another Phase III, open-label study (NCT01851330)
examined 8 weeks versus 12 weeks of ledipasvir plus sofos-
buvir therapy with or without ribavirin in 647 treatment-
naı¨ve, noncirrhotic patients with genotype 1 infection.57
Ninety-four percent of patients achieved SVR12 after 8
weeks of ledipasvir plus sofosbuvir therapy, compared to 95%
after 12 weeks or 93% after 8 weeks with ribavirin. The au-
thors found no additional benefit for the addition of ribavirin
or for extending therapy from 8 weeks to12 weeks.
Sofosbuvir and ribavirin in genotypes 2 and
genotype 3
Sofosbuvir has also been examined in single DAA therapy
with ribavirin for patients with genotypes 2 or 3. Patients
with genotypes 2 or 3 who are ineligible for or unresponsive
to interferon therapy have few treatment options. In a pair
of Phase III studies (NCT01542788 and NCT01604850) in
patients with genotype 2 or genotype 3, 278 interferon-
ineligible patients were randomly assigned to 12 weeks oftherapy with ribavirin and either sofosbuvir or placebo, and
201 previously treated patients were assigned to 12 weeks
or 16 weeks of sofosbuvir and ribavirin.58 The SVR12 rate
was 78% with sofosbuvir and 0% with placebo among
interferon-ineligible patients. The SVR12 rate among pre-
viously treated patients was 50% with 12 weeks of therapy,
compared to 73% after 16 weeks. Cirrhotic patients and
patients with genotype 3 had lower response rates. The
authors noted that the extension to 16 weeks of therapy
significantly improved the response rates among previously
treated patients with genotype 3.
Another recent study examined sofosbuvir and ribavirin
in therapy in cirrhotic or previously treated patients with
genotypes 2 or 3. Four hundred nineteen patients (21 pa-
tients with genotype 2 and 328 patients with genotype 3;
21% were cirrhotic and 58% were previously treated) were
randomly assigned to receive 12 weeks of sofosbuvir and
ribavirin or a placebo (NCT01682720).59 However, in light of
new information,58 the study was unblinded and all patients
with genotype 3 were treated with 24 weeks of sofosbuvir
and ribavirin. Ninety-three percent of patients with geno-
type 2 and 85% of patients with genotype 3 achieved SVR12.
Sofosbuvir and simeprevir
Another recent combination includes sofosbuvir and the PI
simeprevir. In the COSMOS study, 167 treatment-naı¨ve or
prior nonresponder patients were randomized into four
groups treated with simeprevir and sofosbuvir with or
without ribavirin for 12 weeks or 24 weeks.60 Ninety-two
percent of overall patients achieved SVR12, which
included 90% among prior nonresponders with METAVIR
scores F0eF2 and 92% among patients with METAVIR scores
F3eF4. Fatigue, headache, and nausea were the most
common adverse events, but severe adverse events were
reported only in four patients.
ABT-450/r, dasabuvir (ABT-333), and ribavirin
In a Phase IIa open-label study (NCT01306617), 50 treat-
ment-naı¨ve patients or prior nonresponder patients with
genotype 1 received 12 weeks of combination therapy with
150 mg or 250 mg of ritonovir-boosted ABT-450 (a PI),
dasabuvir (a NNI polymerase inhibitor), and ribavirin.61
Among treatment-naı¨ve patients, 95% of the high-dose
group and 93% of the low-dose group achieved SVR12.
Forty-seven percent of the prior nonresponders achieved
SVR12, but three patients relapsed and six patients expe-
rienced viral breakthrough. Adverse events included liver-
enzyme abnormalities, fatigue, nausea, and rash.
ABT-450/r, ombitasvir, dasabuvir, and ribavirin
Several clinical trials have examined triple DAA combina-
tion therapy with ABT-450 with ritonavir (ABT-450/r, a
protease inhibitor), ombitasvir (ABT-267, an NS5A inhibi-
tor), and dasabuvir (ABT-333, a NNI polymerase inhibitor)
with or without ribavirin. In a double-blind, placebo-
controlled Phase III clinical trial (NCT01716585), 631 non-
cirrhotic treatment-naı¨ve patients with genotype 1 were
randomly assigned to 12 weeks of therapy with ABT-450/r,
212 C.N. Hayes, K. Chayamaombitasvir, dasabuvir, and ribavirin or equivalent
placebos.62 The DAA group achieved a SVR12 rate of 96%
(genotype 1a, 95%; genotype 1b, 98%), which was superior
to the 78% SVR12 rate of a historical control group of pa-
tients treated with telaprevir, peginterferon, and ribavirin.
In two other Phase III clinical trials of treatment-naı¨ve
patients with genotype 1 (NCT01767116 and NCT01833533),
419 patients with genotype 1a, and 305 patients with ge-
notype 1b were treated with 12 weeks of ABT-450/r,
ombitasvir, dasabuvir, with or without ribavirin, or equiv-
alent placebos.63 A SVR12 was achieved in 99.5% of patients
with genotype 1b and in 97% of patients with genotype 1a
who received ribavirin, compared to 99% of patients with
genotype 1b. In 90% of patients with genotype 1a, SVR12
was achieved without ribavirin. The rate of virologic failure
was higher in patients with genotype 1a who did not receive
ribavirin, but not in patients with genotype 1b.
Many studies have been performed on treatment-naı¨ve
noncirrhotic patients, although patients with cirrhosis or
those who were nonresponsive to previous interferon
therapy are likely to benefit from interferon-free therapies.
In a Phase III trial (NCT01715415), 394 noncirrhotic patients
with genotype 1 who experienced relapse, partial response,
or null response under previous peginterferon plus ribavirin
therapy were randomly assigned to 12 weeks of therapy
with ABT-450/r, ombitasvir, dasabuvir, and ribavirin or their
corresponding placebos.64 Sustained virological response
was achieved in 96% of patients in the active group
(including 95% of prior relapsers), 100% of prior partial re-
sponders, and 95% of prior nonresponders.
To examine the effect of the interferon-free therapy in
cirrhotic patients, 380 patients with genotype 1 with Child-
Pugh class A compensated cirrhosis were treated for 12
weeks or 24 weeks with ABT-450/r, ombitasvir, dasabuvir,
and ribavirin in an open-label Phase III.65 Ninety-one
percent of patients treated for 12 weeks achieved SVR,
and 96% of patients treated for 24 weeks achieved SVR. Two
percent of patients stopped treatment because of adverse
events such as fatigue, headache, and nausea.
Faldaprevir (BI 201335), deleobuvir (BI 207127),
and ribavirin
In a Phase IIb open-label clinical trial (NCT01132313) of
faldaprevir (a PI) and deleobuvir (a NNI polymerase inhibi-
tor), with or without ribavirin, 362 treatment-naı¨ve pa-
tients with genotype 1 were randomly assigned to five
treatment groups that differed with respect to treatment
duration and deleobuvir dose.66 The SVR12 ranged from 52%
to 69% in the ribavirin groups, but was significantly higher
than in the non-ribavirin group (39%). The SVR12 rates also
varied with respect to the IL28B genotype and were higher
for HCV genotype 1b than for HCV genotype 1a. However,
the pharmaceutical company Boehringer Ingelheim (Ingel-
heim, Germany) has discontinued development of the drug
because of insufficient efficacy in follow-up studies.
ABT-450/r, ABT-072, and ribavirin
In a Phase IIa open-label single-arm study, 11 treatment-
naı¨ve patients with genotype 1 were treated withritonavir-boosted ABT-450 (PI), ABT-072 (NNI polymerase
inhibitor), and ribavirin for 12 weeks.67 Ninety-one percent
of patients achieved a SVR, although one patient relapsed
36 weeks after the end of treatment. Adverse events
included headache, fatigue, and nausea.
Mericitabine (R7128), danoprevir (RG7227/ITMN-
191), and ribavirin
In a Phase IIb follow-on study (NCT01278134), 169 treat-
ment-naı¨ve patients with genotype 1 were treated with
mericitabine and ritonavir-boosted danoprevir with riba-
virin or placebo for 12 weeks or 24 weeks.68 Relapse rates
were high with the 12-week regimen and ribavirin-free
regimen, primarily because of danoprevir-resistant muta-
tions. Thirty-seven percent of 24-week patients achieved
SVR24, but patients with genotype 1a had much poorer
response (25%) than patients with genotype 1b (64%). The
authors concluded that the SVR rates were poor, although
the combination therapy was safe and well tolerated.
MK-5172, MK-8742, and ribavirin
Results of the Phase II the Study of the Combination
Regimen MK-5172 and MK-8742  Ribavirin in Participants
with Chronic Hepatitis C (C-WORTHy) trial were presented
at the 49th Annual Meeting of the European Association for
the Study of the Liver (EASL 2014). In Part A, 65 non-
cirrhotic, treatment-naı¨ve patients with genotype 1 were
randomized into three treatment arms and treated for 12
weeks with 20 mg or 50 mg of once-daily MK-5172 (a PI) and
MK-8742 (a NS5A inhibitor) with or without ribavirin.69 In
Part B, 91 patients were assigned to three treatment arms
with 50 mg MK-5172/MK-8742/ribavirin for 8 weeks or 12
weeks. Hepatitis C virus RNA was below the lower limit of
quantification (LLQ) at Week 4 in all patients. Ninety-eight
percent of patients treated with the MK-5172/MK-8742
achieved SVR12, whereas 94% of patients treated with
MK-5172/MK-8742/ribavirin achieved SVR12. The most
common adverse events included fatigue, headache, and
nausea. In another trial of the C-WORTHy study, 254 pa-
tients with cirrhotic or previous null response were
randomly assigned to treatment with 12 weeks or 18 weeks
of MK-5172/MK-8742 therapy with or without ribavirin.70
Patients showed rapid suppression of the virus, with
59e73% of patients reaching the HCV RNA LLQ by Week 2
and 94e100% of patients reaching the LLQ at Week 4. The
most common adverse events were fatigue, headache, and
nausea.
Conclusion
The large number of DAAs currently under development and
the encouraging results in clinical trials are cause for
optimism in successfully treating HCV. However, as addi-
tional DAAs are approved for clinical use, clinicians may
face complex choices and treatment guidelines. This will
allow greater potential for personalized therapies and
require increased need for resistance monitoring and
stopping rules. Future clinical trials will examine new drugs
and are likely to consider optimal DAA combinations and
Emerging treatments for chronic HCV 213evaluate the ongoing need for ribavirin, balancing safety,
efficacy, and barriers to resistance. Upcoming clinical trials
should also address remaining difficult-to-treat patient
populations with unmet needs, including pre- and post-liver
transplantation patients and uremic or HCV/HIV coinfected
patients. In principle, all patients could be treated with
interferon-free DAA combination therapies; however, in
developing countries or in the event of strong resistance or
other complications, interferon and ribavirin are likely to
continue to have an important role.71 In this scenario, pa-
tient screening may help to identify the most effective and
cost-effective treatment approaches in situations of
limited resources.Acknowledgments
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